Journal of Clinical Oncology· Baoqing Chen·收录于· 14 小时前AI 评分17
替雷利珠单抗联合放化疗治疗食管鳞癌：回应治疗耐受性、随访时长与NRF2通路维持免疫治疗暴露的商榷
Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”
AI 导读
针对EC-CRT-002研究中替雷利珠单抗联合放化疗治疗食管鳞状细胞癌的两篇读者来信，作者就治疗耐受性与随访时长、以及NRF2通路状态与维持免疫治疗暴露等问题作出回应。
来源：Journal of Clinical Oncology · ascopubs.org